Oxford BioMedica licenses LentiVector technology to Sigma-Aldrich

By E. Janene Geiss

Philadelphia, Oct. 20 - Oxford BioMedica and Sigma-Aldrich announced Thursday an agreement to commercialize Oxford BioMedica's LentiVector technology for the reagent and research tool market.

Oxford BioMedica will receive an upfront payment, annual minimum payments and royalties for Sigma-Aldrich's exclusive right to sublicense the technology for research purposes, according to a company news release.

Sigma-Aldrich has plans to develop new products based on the technology for sale to its customers in the pharmaceutical, biotechnology and academic sectors.

The deal also includes Sigma-Aldrich's commitment of an equity investment of $5 million in Oxford BioMedica to be completed before Jan. 31, 2006.

"This partnership will allow Oxford BioMedica to derive maximum benefit from research applications of the technology, while keeping the primary business development focus on the commercialization of our therapeutic product pipeline," Peter Nolan, Oxford BioMedica's senior vice president, said in the release.

Oxford BioMedica, a spin-off of Oxford University, is a biopharmaceutical company specializing in development of gene-based therapeutics for oncology and neurotherapy.

Sigma-Aldrich is a St. Louis-based life science and high technology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.